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Introduction {#jah32100-sec-0004}
============

Diseases of the thoracic aorta are increasing in prevalence worldwide.[1](#jah32100-bib-0001){ref-type="ref"}, [2](#jah32100-bib-0002){ref-type="ref"} In the United Kingdom (UK), between 1999 and 2010, hospital admissions for thoracic aortic dissection increased from 7.2 to 8.8 and for thoracic aortic aneurysm from 4.4 to 9.0 per 100 000 inhabitants.[3](#jah32100-bib-0003){ref-type="ref"} These diseases have a high mortality; in the UK, mortality rates for thoracic aortic dissection and aneurysm are 3.2 and 7.5 per 100 000 inhabitants, respectively.[3](#jah32100-bib-0003){ref-type="ref"} There is evidence of regional variation in clinical outcomes for patients with thoracic aortic disease (TAD)[4](#jah32100-bib-0004){ref-type="ref"}, [5](#jah32100-bib-0005){ref-type="ref"}, [6](#jah32100-bib-0006){ref-type="ref"}, [7](#jah32100-bib-0007){ref-type="ref"}, [8](#jah32100-bib-0008){ref-type="ref"}, [9](#jah32100-bib-0009){ref-type="ref"}, [10](#jah32100-bib-0010){ref-type="ref"}, [11](#jah32100-bib-0011){ref-type="ref"}; for example, operative mortality rates for acute type A dissection, the most common acute presentation of TAD, range from 2.8% to 47.6% between centers.[4](#jah32100-bib-0004){ref-type="ref"}, [9](#jah32100-bib-0009){ref-type="ref"}, [10](#jah32100-bib-0010){ref-type="ref"}, [11](#jah32100-bib-0011){ref-type="ref"}, [12](#jah32100-bib-0012){ref-type="ref"}, [13](#jah32100-bib-0013){ref-type="ref"}, [14](#jah32100-bib-0014){ref-type="ref"}, [15](#jah32100-bib-0015){ref-type="ref"}, [16](#jah32100-bib-0016){ref-type="ref"} This may reflect differences in socioeconomic, ethnic, and other demographic characteristics of local populations, but there is also evidence of variation in the provision of aortic services in the UK and elsewhere.[7](#jah32100-bib-0007){ref-type="ref"}, [10](#jah32100-bib-0010){ref-type="ref"}, [16](#jah32100-bib-0016){ref-type="ref"} Targeting unwarranted variation is a key objective for health services as a means of improving the quality and equity of access to care.[17](#jah32100-bib-0017){ref-type="ref"}

The aim of the current study was to evaluate the contribution of unwarranted variations in care to regional differences in outcome observed in TAD patients in England and identify areas of structure and process for quality improvement.

Methods {#jah32100-sec-0005}
=======

Study Design {#jah32100-sec-0006}
------------

We measured mortality (primary outcome) along with a range of other important measures of quality, such as equity of access, timeliness of surgery, and the effect of treatment on longer‐term patient outcomes in national databases used to monitor quality of care by National Health Service (NHS) England; the National Adult Cardiac Surgery Audit (NACSA), used by the National Institute for Comparative Outcomes Research (NICOR) to monitor cardiac surgeon and unit specific hospital mortality, and the administrative NHS database Hospital Episode Statistics (HES), used by Dr Foster to measure hospital performance. We also asked cardiac surgical units in England to complete a questionnaire on the structure and organization of TAD services. Because there is no agreed service specification for TAD services in England and elsewhere,[7](#jah32100-bib-0007){ref-type="ref"}, [10](#jah32100-bib-0010){ref-type="ref"}, [16](#jah32100-bib-0016){ref-type="ref"}, [18](#jah32100-bib-0018){ref-type="ref"}, [19](#jah32100-bib-0019){ref-type="ref"} and current recommendations for service organization are not evidence based,[20](#jah32100-bib-0020){ref-type="ref"}, [21](#jah32100-bib-0021){ref-type="ref"}, [22](#jah32100-bib-0022){ref-type="ref"}, [23](#jah32100-bib-0023){ref-type="ref"}, [24](#jah32100-bib-0024){ref-type="ref"} we also conducted a parallel systematic review of existing studies that have considered quality standards for TAD service delivery. Data were extracted from the HES and the NICOR NACSA registry, according to The REporting of studies Conducted using Observational Routinely collected health Data (RECORD) statement (Table [S1](#jah32100-sup-0001){ref-type="supplementary-material"}).[25](#jah32100-bib-0025){ref-type="ref"} The need to obtain informed consent from patients was waived by the University of Leicester Research Governance Office because the identifiable information was either removed or pseudonymized. The study was approved by the NICOR NACSA Research Board (study reference 14‐ACS‐25). A systematic review and meta‐analysis on the standard of care for the management of TAD was also performed and adhered to MOOSE and PRISMA guidelines (Tables [S2](#jah32100-sup-0001){ref-type="supplementary-material"} and [S3](#jah32100-sup-0001){ref-type="supplementary-material"}).[26](#jah32100-bib-0026){ref-type="ref"}, [27](#jah32100-bib-0027){ref-type="ref"}

Data Sources and Study Populations {#jah32100-sec-0007}
----------------------------------

Data, outcomes, and study populations obtained from HES and NICOR NACSA registries are fully reported in Data [S1](#jah32100-sup-0001){ref-type="supplementary-material"}. Briefly, HES is the national hospital administrative database for England and covers all admissions to public (NHS) hospitals in the country.[28](#jah32100-bib-0028){ref-type="ref"} The data contain demographic, administrative, and clinical information, including procedures and operations (Table [S4](#jah32100-sup-0001){ref-type="supplementary-material"}). The NICOR NACSA registry (version 4.1.2) contains prospectively data for all English adult patients undergoing major thoracic aortic surgery and undergoes robust validation and checking procedures to maintain data quality.[16](#jah32100-bib-0016){ref-type="ref"}, [29](#jah32100-bib-0029){ref-type="ref"}, [30](#jah32100-bib-0030){ref-type="ref"}, [31](#jah32100-bib-0031){ref-type="ref"}

To complement the NACSA study, we also contacted the Society for Cardiothoracic Surgery Unit Representatives for every cardiac surgery unit in England assessing their current service organization for TAD. Surgeons were queried on the presence of a dedicated aortic team, a specific on‐call rota for thoracic aortic disease, a hybrid theater, and an aortic multidisciplinary team (MDT) recognized in the consultant job plan.

The study was approved by the NICOR NACSA Research Board (study reference 14‐ACS‐25). The need to obtain informed consent from patients was waived by the University of Leicester Research Governance Office because the identifiable information was either removed or pseudonymized.

Systematic Review and Meta‐Analysis {#jah32100-sec-0008}
-----------------------------------

Electronic search strategy, objectives, criteria for study selection, eligibility, data collection, and assessment of study quality were published online and registered in the PROSPERO International Prospective Register of Systematic Reviews (PROSPERO registry---CRD42015024137).[32](#jah32100-bib-0032){ref-type="ref"}

Briefly, 3 reviewers systematically searched electronic databases (MEDLINE \[PubMed and Ovid\], Embase, SCOPUS, and Cochrane Library) without date or language restriction from inception to the end of December 2015. Our keywords and MeSH terms pertinent to the exposure of interest were used in relevant combinations and included: "aorta", "aorta, thoracic", "aorta, thoracoabdominal", "aortic aneurysm", "aortic dissection", "standard of care", "health care", "treatment outcome", "hospital mortality", "hospital volume", "surgeon volume", "volume outcome relationship", "teaching hospital", and "urban hospital". In addition, the reference lists of all retrieved articles were reviewed for further identification of potentially relevant studies that were not previously identified.

All adult major thoracic aortic procedures were considered. Exposures of interest included hospital volume activity, generally defined as yearly number of major aortic operations performed, subdivided in low‐ or high‐volume, surgeon volume, presence of multidisciplinary thoracic aortic surgery program, and teaching/urban hospital status. The primary outcome of interest was all‐cause mortality in hospital or within 30 days from index admission or procedure. Secondary outcomes included postoperative stroke, re‐exploration for bleeding/tamponade, postoperative renal failure, and total length of hospital stay. Inclusion and exclusion criteria for qualitative/quantitative analyses were summarized according to PICOS approach (Table [S5](#jah32100-sup-0001){ref-type="supplementary-material"}).

Year of publication, study design, country, sample size, recruitment period, inclusion and exclusion criteria, measured outcomes, aortic center configuration, and definition of low‐ and high‐volume threshold, baseline patient demographics (age, sex), and outcomes among low‐ and high‐volume groups were extracted. Quality assessment was performed using the Newcastle‐Ottawa Scale (NOS).[33](#jah32100-bib-0033){ref-type="ref"}

Statistical Analysis {#jah32100-sec-0009}
--------------------

### HES cohort {#jah32100-sec-0010}

Outcomes were calculated as crude proportions and adjusted for a number of patient factors as listed in Tables [S6](#jah32100-sup-0001){ref-type="supplementary-material"} and [S7](#jah32100-sup-0001){ref-type="supplementary-material"}. Comorbidity information was taken from the index admission or any admission for any reason in the previous year. All outcomes were binary, so logistic regression was used. These models were hierarchical with 2 levels, with random effects for each county. Predicted probabilities for each patient were derived from the fixed‐effects part of the model.[34](#jah32100-bib-0034){ref-type="ref"} Hierarchical models adjust for the clustering of patients within county and allow the estimation of the proportion of variation in the outcome that is attributable to each level of the model (ie, to patient factors and to county). To obtain adjusted outcome rates by county, observed and predicted probabilities were summed by county, with the former divided by the latter to obtain relative risks. These were then multiplied by the national crude outcome rate to obtain adjusted rates. Rates were put onto funnel plots with 95% and 99.8% control limits, the latter to determine how many counties were statistical outliers. To assess model fit, deviance residuals were plotted and the Hosmer‐Lemeshow risk deciles and chi‐squared value also inspected. Discrimination was assessed using the area under the receiver‐operating characteristic curve (c statistic). This was done for logistic regression without adjustment for clustering, because there is no consensus over how to calculate the equivalent measures for hierarchical models.[35](#jah32100-bib-0035){ref-type="ref"} As well as random effects for each geographical area, random slopes were tried in the model for receiving surgery for several binary patient factors: age over 75 versus younger, 1 or more versus none of 5 major comorbidities, dissection versus none, and aneurysm versus none. This was to see whether any of these factors had different effects on the outcome depending on the area. We did not find such effects and therefore report only results from using fixed slopes. Finally, obtained rates for TAD treatment by county as well as 6‐month mortality for treated and untreated patients were mapped using ArcMap version 10.3 (ESRI, Redlands, CA).

### NACSA cohort {#jah32100-sec-0011}

Categorical and dichotomous variables were summarized as absolute number and percentage. Non‐normally distributed continuous data were summarized as medians and interquartile ranges (IQRs). The effects of operational and institutional characteristics on in‐hospital mortality were assessed using multiple logistic regression models. Relevant patient‐level variables were offered to the models to adjust for any potential confounding factors. Results of the regression analyses were expressed as odds ratios (ORs) and 95% CIs. Box and whisker plots were used to present case mix distributions by center: These plots show the 25th percentile, median and 75th percentile of a given distribution at the bottom, middle and top of the boxes, respectively, then the mean is then plotted as a dot, and the lower and upper whiskers then represent the 5th and 95th percentiles, respectively. Scatter plots were generated to assess the relationship between observed in‐hospital mortality and volume, and ordinary least squares (OLS) regression lines were included for visual inspection. Statistical analyses were performed with SAS software (version 9.3; SAS Institute Inc., Cary, NC). In all cases, *P*\<0.05 was considered statistically significant.

### Systematic review and meta‐analysis {#jah32100-sec-0012}

Treatment effect on operative outcomes is reported as ORs with a 95% CI. Yates correction was implemented if a cell contained a zero in the 2×2 contingency table.[36](#jah32100-bib-0036){ref-type="ref"} Individual ORs (OR \<1: high volume centers better) and variance were computed by using number of events and sample size and pooled by using Mantel--Haenszel method and random‐effects model.[37](#jah32100-bib-0037){ref-type="ref"} A fixed‐effects model was also computed as sensitivity analysis. A subgroup analysis according to the primary aortic pathology (aneurysm vs aortic dissection) was performed, being a possible significant effect modifier. Finally, to account for inherent patient selection bias related with an observational study design, individual risk‐adjusted ORs for the primary endpoint were obtained when reported, and pooled adjusted risk estimates were computed by using log transformation and a generic inverse‐variance weighting method. I^2^ statistic was used to estimate the percentage of total variation across studies attributed to heterogeneity rather than chance. Suggested thresholds for heterogeneity were used, with I^2^ values of 25% to 49%, 50% to 74%, and ≥75%, indicative of low, moderate, and high heterogeneity.[38](#jah32100-bib-0038){ref-type="ref"} Publication bias was evaluated using visual inspection of funnel plot asymmetry and by Egger\'s test.[39](#jah32100-bib-0039){ref-type="ref"} *P*\<0.05 was used as the level of significance and 95% CIs were reported where appropriate. Statistical analysis was conducted using meta package for R (version 4.3‐2; R Foundation for Statistical Computing, Vienna, Austria).[40](#jah32100-bib-0040){ref-type="ref"}, [41](#jah32100-bib-0041){ref-type="ref"}

Results {#jah32100-sec-0013}
=======

HES Cohort {#jah32100-sec-0014}
----------

Of 26 551 patients with a TAD admission in England between 2004--2005 and 2010--2011, 25 282 had not had such an admission in the previous 5 years and were defined as index admissions. Seven hundred thirty‐four (2.8%) were excluded because of lack of area identifiers, leaving a final population of 24 548 adult patients coded as having a new diagnosis of TAD. Of these, 16 448 (67%) were affected by aneurysms, 6345 (25.9%) by dissections, and 1665 (6.8%) by unspecified TAD. A total of 5445 (22%) underwent treatment (surgical and/or endovascular) within 6 months of diagnosis. The 6‐month mortality in treated patients was 17.7% and in untreated patients was 30%. Patient characteristics are summarized in Table [1](#jah32100-tbl-0001){ref-type="table-wrap"}.

###### 

National Crude Outcome Rates Split by Age, Major Comorbidity, and TAD Subtype (HES Cohort)

  Patient Factor[a](#jah32100-note-0005){ref-type="fn"}   Receiving Operation (%)   Nonemergent Operation (%)   Postoperative Mortality (%)   Mortality in Patients With No Operation (%)
  ------------------------------------------------------- ------------------------- --------------------------- ----------------------------- ---------------------------------------------
  Age \<75, y                                             31.6                      54.4                        14.0                          18.4
  Age 75+, y                                              11.6                      52.6                        24.3                          40.7
  TAD: dissection                                         19.4                      10.9                        21.5                          39.9
  TAD: aneurysm                                           15.8                      69.3                        12.5                          26.4
  No major comorbidity                                    27.6                      50.1                        12.2                          27.6
  1+ major comorbidities                                  18.8                      58.2                        21.0                          31.7
  All patients combined                                   22.2                      53.7                        16.7                          30.5

HES indicates Hospital Episodes Statistics; TAD, thoracic aortic disease.

Patients with neither dissection nor aneurysm recorded have been omitted from the rows for TAD subtype. Major comorbidities covered ischemic heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, renal disease, and cancer. Mortality is defined as death in or out of hospital within 6 months of diagnosis or operation.
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### Variation attributable to patient‐related factors {#jah32100-sec-0015}

Predictive variables for receiving treatment, or an emergent procedure, are reported in Table [S6](#jah32100-sup-0001){ref-type="supplementary-material"}. Briefly, increasing age, pre‐existing diabetes mellitus, comorbidities, and a diagnosis of cancer were associated with a conservative approach. The greater the deprivation status, the lower were the odds of being treated. Patients affected by aortic dissection and comorbid conditions, including ischemic heart disease and congenital and other vascular disorders, were more prone to be treated on an emergent basis. Predictors of 6‐month mortality in treated and untreated patients are summarized in Table [S7](#jah32100-sup-0001){ref-type="supplementary-material"}. In patients receiving treatment, mortality was associated with increasing age, comorbidity presence, and nonelective admission. Emergent/urgent admission, increasing age, severe comorbidity, and the presence of aortic dissection were associated with mortality in untreated patients.

### Variation attributable to non‐patient‐related factors {#jah32100-sec-0016}

Significant variance by county of residence was observed in terms of the percentages of patients receiving treatment within 6 months of their index admission, ranging from 7.6% in Leicestershire to 31.5% in the West Midlands (Figure [1](#jah32100-fig-0001){ref-type="fig"}). The percentage of subjects treated emergently ranged from 29.6% in Merseyside to 67.9% in Durham (Figure [2](#jah32100-fig-0002){ref-type="fig"}). Multilevel modeling confirmed the statistically significant differences in treatment rates by county of residence. A null model containing only random effects for the counties estimated the variance between counties in log odds of treatment as 0.096 (SE, 0.024); adding patient factors to this null model actually increased the estimated between‐county variance (to 0.105; SE, 0.026). To adjust for regional differences in detection rates, the TAD admission rates per 100 000 resident populations for each county were entered into the model. This reduced the between‐county variance in treatment rates by 40% to 0.060 (SE, 0.016). Despite this, the overall number of counties flagged as high or low outliers on funnel plots using 99.8% control limits were very similar to those observed using crude TAD admission rates.

![Geographical variation by county across England with reference to treatment rates in patients diagnosed with thoracic aortic disease (left panel), 6‐month mortality in treated (mid panel) and untreated (right panel) patients. From HES (Hospital Episodes Statistics) cohort data.](JAH3-6-e004913-g001){#jah32100-fig-0001}

![Percentage of patients affected by thoracic aortic disease (TAD) by county and urgency of the operation received (elective vs emergent). From HES (Hospital Episodes Statistics) cohort data.](JAH3-6-e004913-g002){#jah32100-fig-0002}

Regional differences by county were also observed for 6‐month mortality (Figure [1](#jah32100-fig-0001){ref-type="fig"} and Figure [S1](#jah32100-sup-0001){ref-type="supplementary-material"}). For treated patients, risk‐adjusted mortality rates ranged from 6.5% in Oxfordshire to 23.3% in North Yorkshire. Risk‐adjusted mortality rates in untreated patients ranged from 19.4% in Leicestershire to 36.3% in East Sussex. Adding patient factors to the null model reduced the variation in mortality in treated patients attributable to county of origin by 27%, therefore becoming nonsignificant (variance estimate, 0.037; SE, 0.023). A 62% fall in the variation in mortality was observed in untreated patients, although the between‐county variance remained statistically significantly greater than zero, but modest in size (0.027; SE, 0.009).

Using Pearson correlation with counties weighted by their total number of index admissions, we compared the sets of county‐level adjusted outcome rates. The proportion of patients receiving treatment showed positive, but nonsignificant, correlations with the proportion of treatments done nonemergently (ρ=+0.20; *P*=0.209) and the postoperative mortality rate (ρ=+0.25; *P*=0.114). Conversely, the proportion of treated patients demonstrated a positive and statistically significant correlation with the mortality rate in untreated patients (ρ=+0.47; *P*=0.002). This latter relation was driven by patients without dissection: for these patients alone, the correlation was +0.68 (*P*\<0.001), whereas for those with dissection it was −0.28 (*P*=0.079). In order to verify whether the positive correlation between treatment rates and 6‐month mortality in both treated and untreated patients may reflect an underlying difference in access to care, patients\' risk profiles were analyzed. No correlation between the proportion of high‐risk patients treated by county, defined as those in the highest tertile for predicted probability, and mortality rate in the untreated was observed (ρ=+0.17; *P*=0.294).

NACSA Cohort {#jah32100-sec-0017}
------------

We considered that confounders not contained within HES data might also contribute to unwarranted variance. We therefore evaluated regional variance in treatment of TAD using the NACSA registry, which contains validated data on the severity and complexity as well as the treatment of TAD by regional cardiac centers.

### Study cohort {#jah32100-sec-0018}

Of the 219 741 patients that underwent surgery in cardiac surgery centers in England, complete case data were available on 8058 major aortic surgery cases from 29 hospitals that comprised the analysis data set. Patient characteristics and operative details are summarized in Table [2](#jah32100-tbl-0002){ref-type="table-wrap"} and Table [S8](#jah32100-sup-0001){ref-type="supplementary-material"}. All centers provided data on patients operated on root/ascending aorta and aortic arch segments, 28 (96.6%) centers on the descending thoracic aorta, and 17 (58.6%) on the thoracoabdominal aorta (Figure [3](#jah32100-fig-0003){ref-type="fig"}).

###### 

Baseline, Operative, and Mortality Details by Center Volume (Tertiles of Latest 3‐Year Activity) (NACSA Cohort)

  Patient Factor[a](#jah32100-note-0007){ref-type="fn"}   Low‐Volume Center (n=1308)   Medium‐Volume Center (n=2159)   High‐Volume Center (n=4591)
  ------------------------------------------------------- ---------------------------- ------------------------------- -----------------------------
  Demographics                                                                                                         
  Age at operation, y                                     64 (52, 72)                  64 (52, 73)                     64 (51, 73)
  BMI, kg/m^2^                                            27.2 (24.4, 30.2)            27.0 (24.1, 30.4)               26.7 (23.9, 29.9)
  Female sex                                              450 (34.4)                   715 (33.1)                      1526 (33.2)
  Comorbidities                                                                                                        
  Unstable angina                                         77 (5.9)                     114 (5.3)                       181 (3.9)
  NYHA ≥III                                               411 (31.4)                   721 (33.4)                      1184 (25.8)
  MI within 90 days of operation                          58 (4.4)                     72 (3.3)                        138 (3.0)
  Previous cardiac surgery                                150 (11.5)                   307 (14.2)                      795 (17.3)
  Previous aortic surgery                                 27 (2.1)                     71 (3.3)                        237 (5.2)
  Diabetes mellitus                                       102 (7.8)                    175 (8.1)                       276 (6.0)
  Current smoker                                          166 (12.7)                   236 (12.2)                      478 (10.4)
  Hypertension                                            838 (64.1)                   1419 (65.7)                     2779 (60.5)
  Creatinine \>200 μmol/L                                 39 (3.0)                     62 (2.9)                        123 (2.7)
  History of renal dysfunction                            16 (1.2)                     37 (1.7)                        81 (1.8)
  History of pulmonary disease                            153 (11.7)                   267 (12.4)                      554 (12.1)
  History of stroke                                       119 (9.1)                    192 (8.9)                       350 (7.6)
  Neurological dysfunction                                55 (4.2)                     91 (4.2)                        160 (3.5)
  Peripheral vascular disease                             213 (16.3)                   452 (20.9)                      647 (14.1)
  Preoperative nonsinus heart rhythm                      182 (13.9)                   278 (12.9)                      478 (10.4)
  Triple vessel disease                                   68 (5.2)                     134 (6.2)                       169 (3.7)
  Left main stem disease                                  30 (2.3)                     45 (2.1)                        77 (1.7)
  Moderate ejection fraction (30--50%)                    308 (23.6)                   419 (19.4)                      857 (18.7)
  Poor ejection fraction (\<30%)                          57 (4.4)                     92 (4.3)                        179 (3.9)
  PA systolic \>60 mm Hg                                  26 (2.0)                     26 (1.2)                        42 (0.9)
  Preoperative IV nitrates                                62 (4.7)                     118 (5.5)                       231 (5.0)
  Preoperative IV inotropes                               35 (2.7)                     58 (2.7)                        133 (2.9)
  Preoperative ventilation                                22 (1.7)                     42 (2.0)                        102 (2.2)
  Preoperative cardiogenic shock                          88 (6.7)                     100 (4.6)                       154 (3.4)
  Nonelective priority                                    497 (38.0)                   801 (37.1)                      1643 (35.8)
  Urgent priority                                         202 (15.4)                   396 (18.3)                      697 (15.2)
  Emergency priority                                      267 (20.4)                   355 (16.4)                      888 (19.3)
  Salvage priority                                        28 (2.1)                     50 (2.3)                        58 (1.3)
  Dominant pathology                                                                                                   
  Aneurysm                                                697 (53.3)                   1248 (57.8)                     2477 (54.0)
  Dissection                                              326 (24.9)                   481 (22.3)                      1012 (22.0)
  Trauma                                                  7 (0.5)                      7 (0.3)                         36 (0.8)
  "Other"                                                 166 (12.7)                   366 (17.0)                      702 (15.3)
  Data N/A                                                112 (8.6)                    57 (2.6)                        364 (7.9)
  Aortic segment                                                                                                       
  Root/ascending aorta                                    1211 (92.6)                  1798 (83.3)                     3839 (83.6)
  Aortic arch                                             75 (5.7)                     275 (12.7)                      412 (9.0)
  Descending aorta                                        17 (1.3)                     58 (2.7)                        245 (5.3)
  Thoracoabdominal aorta                                  5 (0.4)                      28 (1.3)                        95 (2.1)
  Surgical data                                                                                                        
  Concomitant valve operation                             948 (72.5)                   1339 (62.0)                     3032 (66.0)
  Concomitant CABG operation                              237 (18.1)                   399 (18.5)                      846 (18.4)
  Concomitant "other" cardiac operation                   510 (39.0)                   728 (33.7)                      1408 (30.7)
  CPB time, min                                           178 (129, 240)               152 (114, 208)                  162 (116, 229)
  ACC time, min                                           114 (82, 154)                104 (74, 136)                   105 (75, 143)
  Circulatory arrest time, min                            26 (18, 37)                  25 (17, 34)                     27 (18, 39)
  Outcome                                                                                                              
  In‐hospital mortality                                   138 (10.6)                   206 (9.5)                       404 (8.8)

ACC indicates aortic cross‐clamp; BMI, body mass index; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; IV, intravenous; NACSA, National Adult Cardiac Surgery audit; N/A, not available; NYHA, New York Heart Association; PA, pulmonary artery.

Numerical data are expressed as median and interquartile range (IQR); categorical data as absolute number (percentage).
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![Activity (total number of procedures) (A) and in‐hospital mortality rate (B) by center, by most distal aortic segment; patient risk profile by center expressed by EuroSCORE II (C). From NACSA (National Adult Cardiac Surgery Audit) cohort data. Results of the national survey assessing current service organization for thoracic aortic disease in cardiac surgery centers across England; surgeons were queried on the presence of a dedicated aortic team, a specific on‐call rota for thoracic aortic disease, a hybrid theater, and an aortic multidisciplinary team (MDT) recognized in the consultant job plan (D): The presence of a vertical bar for a given center means that that center had the particular feature given in the chart key.](JAH3-6-e004913-g003){#jah32100-fig-0003}

### Variation attributable to patient‐related factors {#jah32100-sec-0019}

There were differences between centers with respect to predicted operative risk (Figure [3](#jah32100-fig-0003){ref-type="fig"}C); the median calculated logistic EuroSCORE of in‐hospital mortality ranged from 4.6% to 9.1%. Pathology, emergent treatment, and the most distal aortic surgery segment treated (case complexity) were important determinants of hospital mortality (Table [3](#jah32100-tbl-0003){ref-type="table-wrap"}).

###### 

Unadjusted and Risk‐Adjusted In‐Hospital Mortality Effects (NACSA Cohort)

                                                              Frequency   Observed Mortality (%)   Unadjusted OR (95% CI)   Adjusted OR (95% CI)
  ----------------------------------------------------------- ----------- ------------------------ ------------------------ ----------------------
  Aortic segment[a](#jah32100-note-0008){ref-type="fn"}                                                                     
  Root/ascending aorta                                        6848        8.3                      Reference                Reference
  Aortic arch                                                 762         13.3                     1.75 (1.42, 2.16)        1.86 (1.47, 2.35)
  Descending aorta                                            320         15.3                     1.86 (1.38, 2.51)        2.30 (1.66, 3.18)
  Thoracoabdominal aorta                                      128         22.7                     1.91 (1.18, 3.09)        2.75 (1.67, 4.56)
  Activity tertile[b](#jah32100-note-0009){ref-type="fn"}                                                                   
  Low‐volume (latest 3 years\' activity)                      1308        10.6                     Reference                Reference
  Medium‐volume (latest 3 years\' activity)                   2159        9.5                      0.89 (0.71, 1.12)        0.80 (0.62, 1.02)
  High‐volume (latest 3 years\' activity)                     4591        8.8                      0.82 (0.67, 1.00)        0.76 (0.60, 0.95)
  Dominant pathology[c](#jah32100-note-0010){ref-type="fn"}                                                                 
  Aneurysm                                                    4422        4.9                      Reference                Reference
  Dissection                                                  1819        17.2                     4.07 (3.39, 4.89)        2.27 (1.82, 2.82)
  Other                                                       1284        13.2                     2.97 (2.40, 3.67)        2.05 (1.61, 2.61)
  Data N/A                                                    533         9.6                      2.07 (1.50, 2.85)        1.78 (1.26, 2.52)
  Priority[b](#jah32100-note-0009){ref-type="fn"}                                                                           
  Elective                                                    5117        4.8                      Reference                Reference
  Nonelective                                                 2941        17.1                     4.08 (3.47, 4.78)        2.54 (2.09, 3.08)

Adjusted for preoperative comorbidities, operative risk factors, and activity tertile.

Adjusted for preoperative comorbidities, operative risk factors, and most distal aortic segment.

Adjusted for preoperative comorbidities, operative risk factors, most distal aortic segment, and activity tertile.
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### Variation attributable to non‐patient‐related factors {#jah32100-sec-0020}

There were differences between centers with respect to the complexity and volume of cases performed. The largest volume of cases by a single center was 662 and the smallest 117 (Figure [3](#jah32100-fig-0003){ref-type="fig"}A). The percentage of root/ascending aortic operations as a share of total aortic operations ranged from 45.1% to 96.0%, for aortic arch procedures the range was from 1.7% to 32.1%, for descending thoracic aortic procedures from 0.7% to 18.7%, and for thoracoabdominal aortic procedures from 0.2% to 9.9% (Table [S9](#jah32100-sup-0001){ref-type="supplementary-material"} and Figure [S2](#jah32100-sup-0001){ref-type="supplementary-material"}). More‐complex surgery was more common in high‐volume centers. The results of the survey of service organization are shown alongside details of case volume, complexity, and outcome by unit in Figure [3](#jah32100-fig-0003){ref-type="fig"}D. All the units responded to the questionnaire. This demonstrated regional variation in care delivery in terms of the presence of dedicated aortic teams, multidisciplinary aortic team meetings, specific on‐call rotas for aortic emergencies, or use of hybrid operating theaters.

Table [3](#jah32100-tbl-0003){ref-type="table-wrap"} and Table [S10](#jah32100-sup-0001){ref-type="supplementary-material"} show unadjusted and fully risk‐adjusted in‐hospital mortality effects by operation category, tertile of volume activity, dominant pathology, and priority. Case complexity was a principal determinant of in‐hospital mortality. Relative to proximal segments (root/ascending) the adjusted ORs for aortic arch procedures as well as descending thoracic and thoracoabdominal aortic procedures were 1.88 (95% CI, 1.48--2.37), 2.47 (95% CI, 1.77--3.44), and 3.05 (95% CI, 1.82--5.11), respectively. For the increasing volume activity tertiles, the corresponding adjusted risk of in‐hospital mortality relative to low‐volume centers was 0.84 (95% CI, 0.66--1.07) for medium‐volume centers and 0.72 (95% CI, 0.57--0.89) for high‐volume centers (Table [4](#jah32100-tbl-0004){ref-type="table-wrap"}). Similar results were observed when cases where stratified by most distal segment, as well for the OLS regression analyses that demonstrated lower mortality in centers with high‐volume activity (Figure [S3](#jah32100-sup-0001){ref-type="supplementary-material"}).

###### 

Mortality Rates by Volume Center Activity (NACSA Cohort)

                                                            Frequency   Observed Mortality (%)   Unadjusted OR (95% CI)   Adjusted OR (95% CI)
  --------------------------------------------------------- ----------- ------------------------ ------------------------ ----------------------
  Activity tertile[a](#jah32100-note-0012){ref-type="fn"}                                                                 
  Low‐volume (latest 3 years\' activity)                    1308        10.6                     Reference                Reference
  Medium‐volume (latest 3 years\' activity)                 2159        9.5                      0.89 (0.71, 1.12)        0.80 (0.62, 1.02)
  High‐volume (latest 3 years\' activity)                   4591        8.8                      0.82 (0.67, 1.00)        0.76 (0.60, 0.95)
  Activity tertile[a](#jah32100-note-0012){ref-type="fn"}                                                                 
  Low‐volume (6 years\' activity)                           1424        11.1                     Reference                Reference
  Medium‐volume (6 years\' activity)                        2353        9.5                      0.84 (0.68, 1.05)        0.83 (0.66, 1.05)
  High‐volume (6 years\' activity)                          4281        8.6                      0.75 (0.62, 0.91)        0.71 (0.57, 0.88)

NACSA indicates National Adult Cardiac Surgery audit; OR, odds ratio.

Adjusted for preoperative comorbidities, operative risk factors, and most distal aortic segment.

John Wiley & Sons, Ltd

Systematic Review and Meta‐Analysis {#jah32100-sec-0021}
-----------------------------------

Of the 12 804 records identified, 33 eligible observational cohort studies were included in the systematic review, comprising a total of 103 543 patients (Figure [S4](#jah32100-sup-0001){ref-type="supplementary-material"}).[6](#jah32100-bib-0006){ref-type="ref"}, [7](#jah32100-bib-0007){ref-type="ref"}, [8](#jah32100-bib-0008){ref-type="ref"}, [9](#jah32100-bib-0009){ref-type="ref"}, [10](#jah32100-bib-0010){ref-type="ref"}, [11](#jah32100-bib-0011){ref-type="ref"}, [12](#jah32100-bib-0012){ref-type="ref"}, [13](#jah32100-bib-0013){ref-type="ref"}, [14](#jah32100-bib-0014){ref-type="ref"}, [42](#jah32100-bib-0042){ref-type="ref"}, [43](#jah32100-bib-0043){ref-type="ref"}, [44](#jah32100-bib-0044){ref-type="ref"}, [45](#jah32100-bib-0045){ref-type="ref"}, [46](#jah32100-bib-0046){ref-type="ref"}, [47](#jah32100-bib-0047){ref-type="ref"}, [48](#jah32100-bib-0048){ref-type="ref"}, [49](#jah32100-bib-0049){ref-type="ref"}, [50](#jah32100-bib-0050){ref-type="ref"}, [51](#jah32100-bib-0051){ref-type="ref"}, [52](#jah32100-bib-0052){ref-type="ref"}, [53](#jah32100-bib-0053){ref-type="ref"}, [54](#jah32100-bib-0054){ref-type="ref"}, [55](#jah32100-bib-0055){ref-type="ref"}, [56](#jah32100-bib-0056){ref-type="ref"}, [57](#jah32100-bib-0057){ref-type="ref"}, [58](#jah32100-bib-0058){ref-type="ref"}, [59](#jah32100-bib-0059){ref-type="ref"}, [60](#jah32100-bib-0060){ref-type="ref"}, [61](#jah32100-bib-0061){ref-type="ref"}, [62](#jah32100-bib-0062){ref-type="ref"}, [63](#jah32100-bib-0063){ref-type="ref"}, [64](#jah32100-bib-0064){ref-type="ref"}, [65](#jah32100-bib-0065){ref-type="ref"}, [66](#jah32100-bib-0066){ref-type="ref"}, [67](#jah32100-bib-0067){ref-type="ref"} The identified studies (20 multicenter and 13 single‐center) were published between 1994 and 2015. Study characteristics and collected study outcomes are summarized in Tables [S11](#jah32100-sup-0001){ref-type="supplementary-material"} through [S13](#jah32100-sup-0001){ref-type="supplementary-material"}. Quality assessment indicated that 20 of 33 studies were at significant risk of bias (NOS, \<8; Table [S14](#jah32100-sup-0001){ref-type="supplementary-material"}). Twelve observational cohort studies analyzing impact of hospital volume on in‐hospital mortality were identified for the primary analysis, including a total of 14 562 and 16 036 patients who underwent surgery in high‐ and low‐volume centers, respectively. Pooled unadjusted ORs showed that high‐volume centers were associated with a 50% relative risk reduction in mortality when compared with low‐volume centers (Figure [4](#jah32100-fig-0004){ref-type="fig"}, upper panel),[1](#jah32100-note-1004){ref-type="fn"} with a moderate heterogeneity among studies (I^2^=53.4%). No publication bias was found (*P*=0.19; Figure [S5](#jah32100-sup-0001){ref-type="supplementary-material"}). Overall, 9 studies reported on adjusted effect size of hospital volume on mortality (Table [S15](#jah32100-sup-0001){ref-type="supplementary-material"}). Pooled adjusted estimates of individual log ORs confirmed that high‐volume centers were independently associated with a significantly reduced incidence of in‐hospital/30‐day mortality (adjusted OR, 0.56; 95% CI, 0.45--0.70; I^2^=70.2%; Figure [4](#jah32100-fig-0004){ref-type="fig"} lower panel).[7](#jah32100-bib-0007){ref-type="ref"}, [8](#jah32100-bib-0008){ref-type="ref"}, [10](#jah32100-bib-0010){ref-type="ref"}, [13](#jah32100-bib-0013){ref-type="ref"}, [50](#jah32100-bib-0050){ref-type="ref"}, [58](#jah32100-bib-0058){ref-type="ref"}, [59](#jah32100-bib-0059){ref-type="ref"}, [60](#jah32100-bib-0060){ref-type="ref"}, [62](#jah32100-bib-0062){ref-type="ref"} Subgroup analysis showed similar effects for high‐volume centers with respect to both aneurysms and aortic dissection (Figure [S6](#jah32100-sup-0001){ref-type="supplementary-material"}). Pooled estimates did not reveal any significant differences between high‐ and low‐volume centers with reference to postoperative stroke (OR, 1.29; 95% CI, 0.85--1.95; I^2^=58.8%), re‐exploration for bleeding/tamponade (OR, 0.91; 95% CI, 0.72--1.15; I^2^=68.5%), and postoperative renal failure (OR, 0.82; 95% CI, 0.65--1.04; I^2^=77.6%; Figure [S7](#jah32100-sup-0001){ref-type="supplementary-material"}). Centers that introduced a specific multidisciplinary TAD program also reported a significant reduction in mortality (OR, 0.35; 95% CI, 0.13--0.96) although with significant heterogeneity (I^2^=75.7%; Figure [S8](#jah32100-sup-0001){ref-type="supplementary-material"}). Surgeon volume (high‐ vs low‐volume surgeon) and hospital status (teaching vs nonteaching hospitals and urban vs rural hospitals) had no effect on hospital outcomes (Figures [S9](#jah32100-sup-0001){ref-type="supplementary-material"} and [S10](#jah32100-sup-0001){ref-type="supplementary-material"}).

![Forest plot with unadjusted (top) and adjusted (bottom) risk estimates for in‐hospital/30‐day mortality in high‐ versus low‐volume hospitals. OR indicates odds ratio.](JAH3-6-e004913-g004){#jah32100-fig-0004}

Discussion {#jah32100-sec-0022}
==========

The current study has demonstrated significant regional variation in access to treatment, the organization of clinical services, and mortality for patients with TAD in England. An analysis of HES data demonstrated that the variation in the proportion of TAD patients treated within 6 months of diagnosis ranged from 7.6% to 31.5% among counties and remained statistically significant after adjustment for potential confounders, including comorbidity, deprivation, disease severity, and population density. Regional variation was not associated with differences in mortality rates for patients that received treatment, but was associated with differences in mortality in those that did not receive treatment, implying that inequity in access to care has important effects on outcome. The analysis of NASCA data indicated wide regional variation in the volume and complexity of TAD cases undertaken in English cardiac centers. Centers undertaking higher volumes were more likely to treat more‐complex disease and had lower risk‐adjusted mortality. A systematic review that attempted to benchmark service specifications for TAD indicated that patients treated by multidisciplinary teams in high‐volume centers have better clinical outcomes. A survey of structure and processes indicated that this standard of care is not consistently available to patients in England. In addition, our systematic literature search confirmed a world‐wide knowledge gap with respect to the safest, most effective referral model/organization of services for the management of TAD. Neither was identified the minimum service specification for centers that undertake interventions on the thoracic aorta.

To our knowledge, this is the first nation‐wide analysis of the quantity and quality of care for patients with TAD. The study used prospectively collected data from 2 large independent national databases used by the NHS to monitor quality. These contain data on every patient presenting to hospital with TAD or undergoing surgery for TAD in English hospitals. The limitations are those of all registry analyses, notably the risks of confounding and other sources of bias, including variable data quality. We attempted to minimize confounding by adjusting for a large number of baseline patient‐related factors, including demographics, social deprivation, comorbidity, and presentation. Detection bias was mitigated by using objective measures of outcome and exposures of interest. The NACSA database uses consistent, well‐defined definitions of exposures and outcomes and undergoes regular internal and external quality assurance processes. Being an administrative database, HES is more likely to have variations in data quality by hospital; under‐recording of comorbidities, for instance, is a well‐known limitation. For the TAD diagnosis date, we used the date of first recording of TAD in 1 of the diagnosis fields or the date of the TAD procedure if the patient had no earlier TAD admission, implying some uncertainty in the actual diagnosis date. However, certain fields, such as for the primary diagnosis and procedure, have been shown to be reliable by a recent systematic review.[68](#jah32100-bib-0068){ref-type="ref"} A further limitation is that it was not possible to link the HES and NACSA analyses to further explore potential reasons for variability in care. This is because the geographical regions served by individual cardiac centers often overlap. The 2 cohorts also considered different time periods; this was attributed to the availability of complete, cleaned HES data to March 2011, and the availability of data that used consistent definitions for aortic disease in the NACSA database between 2007 and 2013. Our analyses did not specifically consider the role of thoracic endovascular aortic repair (TEVAR). It has been suggested that this has important effects on the mortality of aortic disease, and almost all studies have shown excellent operative mortality rates post‐TEVAR compared to open repair, with even higher survival rates after emergent aortic procedures.[57](#jah32100-bib-0057){ref-type="ref"}, [69](#jah32100-bib-0069){ref-type="ref"} The total numbers of TEVARs listed in the HES database to 2011 were small (n=532), however, preventing useful and detailed analysis.

In addition, our analysis did not account for the potential impact of surgical techniques adopted across English units in the outcomes of TAD patients undergoing surgery. Rates and modality of circulatory arrest used during complex TAD operation, arterial cannulation, and cerebral protection strategies per center were not collected in HES and NACSA databases. This precluded further analyses and the possibility to evaluate these surgical strategies as an additional measure of the quality of care in TAD patients, although arterial cannulation strategies and cerebral protection strategies have been proved to influence operative outcomes in aortic surgery.[70](#jah32100-bib-0070){ref-type="ref"}, [71](#jah32100-bib-0071){ref-type="ref"}

The systematic review was limited in that it relied on the reported information on confounding variables that were controlled for; consistent analyses of all studies can be done only when data on individual patients are combined. Many of the included studies were at risk of bias, and there was substantial heterogeneity in many of the effect estimates. We speculate that this reflected differences in the definitions of exposures of interest, including the definition of a high case volume or what constituted an aortic multidisciplinary team. For example, the definition of high versus low volume was defined, in some studies, as annualized activity versus study period activity, with the numbers of cases expressed varyingly as tertiles or medians.[2](#jah32100-note-1005){ref-type="fn"}

These limitations notwithstanding, this study has demonstrated variability in the quality of care for patients with TAD that appears to be unwarranted. This is a common finding in studies of variation in access to care for patients with cardiovascular disease in England and elsewhere.[17](#jah32100-bib-0017){ref-type="ref"}, [72](#jah32100-bib-0072){ref-type="ref"} Some of the contributory factors to variation identified in this report, such as social deprivation, require complex and difficult solutions; however, variations in structure and processes of care are more readily addressed. For example, service specifications for the provision of vascular surgery in England have led to substantive reorganization of care pathways, the concentration of multidisciplinary expertise in teams, and significant improvements in key markers of quality, such as mortality following elective aneurysm repair.[73](#jah32100-bib-0073){ref-type="ref"}, [74](#jah32100-bib-0074){ref-type="ref"} In the current study, higher‐volume units and those undertaking significant numbers of more‐complex procedures were more likely to have structures in place that were identified in the systematic review as being associated with better outcomes, specifically hybrid operating theatres, and adequately resourced MDT aortic teams. On the basis of these results, we suggest that these structures should be included in any future service specification for thoracic aortic disease. The definition of an adequate unit volume is more difficult; the NASCA data identified units in the lowest tertile of total cases (\<32 cases per year) as having a higher mortality, often with a denominator that included a less‐complex caseload. However, the current study did not specifically address whether this reflects outcomes following the treatment of emergent patients. This is important: Patients with acute type A dissection who do not receive treatment die at a rate of 1% to 2% per hour during the first day and almost half die by 1 week.[75](#jah32100-bib-0075){ref-type="ref"} A reduction in the numbers of units providing emergency services should be balanced by the increase in risk posed by delays in treatment. However, both HES and NACSA databases do not account for information regarding the referral time, interhospital coordination, and transport of patient affected by TAD, especially in the emergent setting, and we were unable to investigate this important aspect of quality of care.[56](#jah32100-bib-0056){ref-type="ref"}

The results of the NASCA analysis also indicated uncertainty as to whether the volume outcome relationship applied to all segments of the aorta, although this may be attributable to a smaller sample size for more‐distal segments resulting in less precision in the estimates. The systematic review did not indicate that surgeon volume was associated with outcome. This may also reflect the limits of precision when evaluating small numbers of surgeons, the majority of whom undertake low numbers of cases. Alternatively, as suggested by the systematic review, it may be the structures and process beyond that surgeon that are critical determinants of outcome.

The present analyses also identified potential sources of unwarranted variation that will not be addressed solely by reconfiguration of specialist teams, for example, with respect to differences in treatment rates for aneurysms versus nonaneurysms, or for emergent versus nonemergent surgery. We speculate that additional barriers to treatment exist before hospital treatment. This variation can be addressed by guidelines for screening, for example, in first‐degree relatives of patients with acute aortic syndromes or bicuspid aortic valves, the use of appropriate imaging, and referral to the TAD service. However, a barrier to the development of these processes is the absence of evidence from randomized trials as to how TAD should be diagnosed and treated. Recent guidelines were based exclusively on evidence from observational analyses and expert opinion.[20](#jah32100-bib-0020){ref-type="ref"}, [21](#jah32100-bib-0021){ref-type="ref"}, [22](#jah32100-bib-0022){ref-type="ref"}

A final comment is that the variation in TAD services that were observed in this study were not apparent when comparing mortality rates in treated patients by center, the current methods used by Dr Foster (HES), and the National Institute for Comparative Outcomes Research (NASCA) for measuring quality in English cardiac uits.[28](#jah32100-bib-0028){ref-type="ref"}, [29](#jah32100-bib-0029){ref-type="ref"}, [30](#jah32100-bib-0030){ref-type="ref"} It is also noteworthy that there was no evidence from the HES analysis that cardiac surgery units preferentially select patients that will have an acceptable outcome following surgery; treatment rates were not determined by patient mortality risk. This refutes a common criticism that the publication of mortality rates in treated patients, as has occurred in England since 2004, contributes to unwarranted variation.[76](#jah32100-bib-0076){ref-type="ref"}

In conclusion, evidence of unwarranted variation in the quality of care supports a reorganization of TAD services in England, with greater emphasis on care delivered by multidisciplinary teams in specialist centers. Similar service specifications and recommendations for standards of care and service delivery for TAD patients have also been commonly observed in other countries, mainly in North America and Europe. However, the safest, most effective referral model/organization of services for the management of TAD has not been identified. Further research must focus on the identification of barriers to early diagnosis and referral for treatment, and comparative trials of treatment options for patients with TAD.
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